ICON Public stock
Price history
+21.45% over the period1 year: from $156.49 (November 17, 2025) to $190.06 (November 16, 2026), +21.45%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $190.06 |
| October 30, 2026 | $211.36 |
| September 30, 2026 | $169.99 |
| August 31, 2026 | $164.99 |
| July 31, 2026 | $163.57 |
| June 30, 2026 | $173.71 |
| May 29, 2026 | $136.07 |
| April 30, 2026 | $118.33 |
| March 31, 2026 | $110.66 |
| February 27, 2026 | $108.14 |
| January 30, 2026 | $180.25 |
| December 31, 2025 | $182.22 |
| November 28, 2025 | $185.00 |
| November 17, 2025 | $156.49 |
At a glance
The company
Provides outsourced clinical research and development services for pharmaceutical, biotechnology and medical device companies worldwide
Latest results
Quarter to September 30, 2026 · EPS $2.66 (estimate $2.64)
TickerLandia's take on ICON Public
- Pricier than usual relative to earnings: P/E on the latest fiscal year 66 vs a median of 29 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 78 vs 38 (+106%) in a group of 9.
- Strong point: Market momentum (86/100 in its group). Weak point: Profitability (14/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−13.23% from the 52-week high
Analysts · 18 analysts
Average target$231.29+21.70% vs. price
Buy 10 · Hold 8 · Sell 0 · Buy
TickerLandia Fingerprint: ICON Public
Compared with similar companies: very strong momentum, very low profitability, and very high risk.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage46
How much it costs relative to what it produces.
Metric Value Position in group Price/book 1.60 10 Price/sales 1.77 13 P/E (trailing 12 months) 77.9 90 Forward P/E 16.8 22 EV/EBITDA 35.5 94 Profitabilityvery low14
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 2.7% 9 Gross margin 23.4% 6 Net margin 5.3% 24 ROE 4.7% 24 ROA 0.9% 9 Earnings stabilityhigh61
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.0% 61 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthlow20
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −63.28% 6 Average revenue growth (3 years) +2.15% 46 Revenue growth (year over year) −2.90% 9 Financial strengthlow31
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.38 69 Net debt/EBITDAcounts in reverse: lower means more financial strength 4.11 10 Interest coverage 2.20 17 Current ratio 1.32 28 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong86
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +32.69% 98 1-year return +19.09% 59 Relative strength (6 months) +63.25% 97 Relative strength (3 months) +19.87% 91 Riskvery high81
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 60.5% 95 Volatility (60 days) 49.5% 76 Beta (1 year) 1.28 73
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
ICON Public is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), ICON Public's P/E today is 65.5, above the median of its last 10 fiscal years (28.5; between 16.2 and 137.6 from 2016 to 2025). ICON Public's P/E (trailing 12 months): 77.9, +106% against the median of a group of 9 similar companies (37.7).
Compared with 9 similar companies
| Metric | ICON Public | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 77.9 | High | |
| Forward P/E | 16.8 | Low | |
| Operating margin | 2.7% | Low | |
| ROE | 4.7% | Middle | |
| Debt/equity | 0.38 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ICON Public. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$2.02B
Latest quarter · Q3 2026
Net income
$122.13M
Latest quarter · Q3 2026
Quarterly net margin
6.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $14.58B
- P/E
- 77.9
- EPS
- $2.50
- Volume
- 966.54K
- Daily trading
- €228.59M
- Dividend yield
- 0.00%
How ICON Public is changing
All resultsRevenue grew 24.2% a year on average over the last 5 years
Operating margin fell from 10.3% to 5.4%
Shares outstanding up 48.2% in 5 years
Returns
ICON Public returns
$1,000 invested in ICON Public 5 years ago, on November 16, 2021, would be worth $666 today: −33.45% in total, −7.82% per year. This is the price return only: dividends are excluded.
| Period | ICON Public | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +11.68% | −3.12% | $1,117 |
| 6 months | +63.31% | +2.07% | $1,633 |
| Year to date | +4.30% | +10.46% | $1,043 |
| 1 year | +21.45% | +13.33% | $1,215 |
| 3 years | −29.36% | +67.73% | $706 |
| 5 years | −33.45% | +60.86% | $666 |
| 10 years | +146.64% | +247.35% | $2,466 |
Over the last 6 months it has done better than 93% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
ICON Public: technical analysis
ICON Public is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 45.1% below its all-time closing high ($346.20, July 16, 2024).
- Trend
- Upward
- RSI (14 sessions)
- 48
- Between 30 and 70
- vs 200-session average
- +29.52%
Support and resistance
Price areas where ICON Public has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$191.33+0.67%3 touches, last on January 27, 2026
- Last price$190.06
- Support$179.47−5.57%4 touches, last on October 6, 2026
- Support$172.65−9.16%3 touches, last on January 20, 2026
- Support$162.32−14.59%2 touches, last on September 18, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.26
- Volatility (60 sessions, annualised)
- 49.7%
- Largest fall in the last year
- −60.54%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
ICON Public: seasonality
Average monthly price change over 29 years
Over the last 29 years, the strongest month for ICON Public has been June: +8.11% on average, positive in 22 years out of 29. The weakest has been October: −2.24% on average, positive in 13 years out of 29. November, the current month, has been positive in 17 years out of 28 (+1.49% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.72% | +1.51% | 16 of 28 |
| February | +0.85% | +1.02% | 15 of 28 |
| March | −1.82% | +2.02% | 17 of 28 |
| April | +0.83% | +0.02% | 14 of 28 |
| May | +2.14% | +3.92% | 17 of 28 |
| June | +8.11% | +4.94% | 22 of 29 |
| July | +6.36% | +9.02% | 24 of 29 |
| August | −1.62% | −1.94% | 12 of 29 |
| September | +0.84% | +1.41% | 17 of 29 |
| October | −2.24% | −0.93% | 13 of 29 |
| November | +1.49% | +2.39% | 17 of 28 |
| December | +3.12% | +2.22% | 18 of 28 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
ICON Public and its competitors
With 40,250 employees, ICON Public Limited Company provides outsourced development and commercialization services to pharmaceutical, biotechnology and medical device companies, as well as to government and public health organizations. Its work covers the clinical development process from compound selection through Phase I-IV studies, including trial management, data solutions, contract staffing and decentralized or hybrid trials. Its testing offering includes bioanalytical, biomarker, vaccine and central laboratory services, and its therapeutic areas include oncology, cardiovascular, central nervous system and infectious diseases.
- Headquarters
- Dublin, Ireland
- Employees
- 40,250
- Founded
- 1990
- Chief executive
- Barry Balfe
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ICON PublicICLR | $14.58B | 2.7% | 77.9 | +63.31% |
| Charles River Laboratories InternationalCRL | $16.19B | 14.3% | 367.4 | +123.10% |
| RevvityRVTY | $17.84B | 16.3% | 70.5 | +59.49% |
| Medpace HoldingsMEDP | $19.12B | 21.4% | 38.0 | +57.36% |
| Guardant HealthGH | $20.52B | -39.4% | — | +52.78% |
| Quest DiagnosticsDGX | $28.56B | 14.9% | 25.9 | +40.23% |
Same industry or related industries, similar size. Compare ICON Public with its competitors · Full profile
